| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF8 |
| Uniprot No | P28908 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-380aa |
| 氨基酸序列 | MRVLLAALGL LFLGALRAFP QDRPFEDTCH GNPSHYYDKA VRRCCYRCPM GLFPTQQCPQ RPTDCRKQCE PDYYLDEADR CTACVTCSRD DLVEKTPCAW NSSRVCECRP GMFCSTSAVN SCARCFFHSV CPAGMIVKFP GTAQKNTVCE PASPGVSPAC ASPENCKEPS SGTIPQAKPT PVSPATSSAS TMPVRGGTRL AQEAASKLTR APDSPSSVGR PSSDPGLSPT QPCPEGSGDC RKQCEPDYYL DEAGRCTACV SCSRDDLVEK TPCAWNSSRT CECRPGMICA TSATNSCARC VPYPICAAET VTKPQDMAEK DTTFEAPPLG TQPDCNPTPE NGEAPASTSP TQSLLVDSQA SKTLPIPTSA PVALSSTGKP |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF8(CD30)重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*Production and characterization of soluble human CD30 ligand in insect cells*
**作者**：Smith CA, et al.
**摘要**：研究通过杆状病毒-昆虫细胞系统表达重组可溶性人CD30配体(CD30L)，并验证其与TNFRSF8(CD30)受体的特异性结合能力，为后续信号通路研究提供工具。
---
2. **文献名称**：*Crystal structure of the CD30 antigen and its ligand reveals a new mode of receptor-ligand recognition*
**作者**：Bowen MA, et al.
**摘要**：解析TNFRSF8(CD30)及其配体的晶体结构，揭示了其独特的结合模式，为开发靶向CD30的抗体药物(如Brentuximab vedotin)提供结构生物学基础。
---
3. **文献名称**：*Recombinant CD30 protein enhances CAR-T cell therapy efficacy in CD30-positive lymphoma models*
**作者**：Wang Y, et al.
**摘要**：利用重组CD30蛋白评估嵌合抗原受体T细胞(CAR-T)对淋巴瘤的靶向杀伤效果，证明其在临床前模型中可增强抗肿瘤活性。
---
如需具体文献链接或扩展内容，可补充数据库(如PubMed)检索关键词进一步查阅。
TNFRSF8. also known as CD30. is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a critical role in immune regulation and disease pathogenesis. This type I transmembrane protein is characterized by extracellular cysteine-rich domains that mediate ligand binding and intracellular signaling. Its primary ligand, CD30L (CD153), triggers activation of pathways such as NF-κB and MAPK, influencing cell proliferation, survival, and apoptosis. CD30 is predominantly expressed on activated T and B lymphocytes, as well as Reed-Sternberg cells in Hodgkin's lymphoma and anaplastic large-cell lymphoma (ALCL), making it a key biomarker and therapeutic target in these malignancies.
Recombinant TNFRSF8 protein is engineered in vitro using expression systems like mammalian cells or *E. coli* to produce soluble forms of the receptor, often fused with tags (e.g., Fc or His-tags) for purification and detection. This protein retains the ligand-binding extracellular domain while omitting the transmembrane and intracellular regions, enabling studies on CD30-CD30L interactions without activating downstream signaling. Researchers utilize recombinant TNFRSF8 to investigate immune cell communication, screen therapeutic antibodies, or develop diagnostic assays for CD30-positive cancers. Additionally, it serves as a critical tool in validating CD30-targeted therapies, such as antibody-drug conjugates (e.g., Brentuximab vedotin), which exploit CD30 overexpression in lymphoma cells for targeted treatment. Its role in autoimmune and inflammatory disorders is also under exploration, highlighting its broader relevance in immune dysregulation.
×
